|1.||Jope, Richard S: 17 articles (02/2014 - 07/2002)|
|2.||Woodgett, James R: 13 articles (06/2015 - 01/2002)|
|3.||Thiemermann, Christoph: 12 articles (09/2011 - 03/2006)|
|4.||Wang, Jian-Zhi: 11 articles (12/2015 - 01/2007)|
|5.||Avila, Jesús: 11 articles (01/2014 - 06/2002)|
|6.||Eldar-Finkelman, Hagit: 11 articles (09/2013 - 07/2002)|
|7.||Hernández, Félix: 9 articles (09/2015 - 12/2002)|
|8.||Koh, Seong-Ho: 9 articles (04/2013 - 07/2005)|
|9.||Wojtaszewski, Jørgen F P: 9 articles (11/2012 - 06/2002)|
|10.||Patel, Satish: 8 articles (12/2011 - 07/2002)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2013 - "This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer's disease (AD) patients. "
06/01/2013 - "Glycogen synthase kinase-3β (GSK3β) expression in a mouse model of Alzheimer's disease: a light and electron microscopy study."
10/01/2012 - "Finally, we study larvae with altered expression of the shaggy gene, a homolog of Glycogen Synthase Kinase-3 (GSK-3), which has been implicated in Alzheimer disease. "
01/01/2016 - "In this review, we have enlightened Glycogen Synthase Kinase-3 which has been considered as a concrete cause for Alzheimer's disease. "
07/01/2014 - "The dysfunction of glycogen synthase kinase-3β (GSK-3β) has been implicated in a number of diseases, including Alzheimer's disease. "
|2.||Bipolar Disorder (Mania)
09/01/2011 - "Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania."
07/01/2011 - "The aim of this study was to examine the relationships between glycogen synthase 3β gene polymorphisms and bipolar I disorder, manic in a Korean sample. "
11/01/2010 - "Preclinical studies have suggested that glycogen synthase kinase-3 (GSK3) is a potential therapeutic target in bipolar disorder, but evidence of abnormal GSK3 in human bipolar disorder and its response to treatment is still lacking. "
08/26/2015 - "TRPM2, a Susceptibility Gene for Bipolar Disorder, Regulates Glycogen Synthase Kinase-3 Activity in the Brain."
03/01/2015 - "Glycogen synthase kinase-3 β (GSK3β) is an intracellular enzyme directly implicated in several neural processes relevant to bipolar disorder (BD) pathophysiology. "
07/05/2015 - "Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3β inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance."
07/01/2003 - "The aim of the present study is to investigate whether Met416Val (M416V) polymorphism of glycogen synthase (GYS1) gene is associated with insulin resistance in type 2 diabetes. "
11/01/2012 - "The prophylactic effect of exercise on lipid-induced insulin resistance may involve augmented TBC1D4 signaling and glycogen synthase activation."
01/01/2011 - "Over-activity and elevated expression of glycogen synthase kinase-3 (GSK-3) has been implicated in the etiology of insulin resistance and Type 2 diabetes. "
12/01/2010 - "Specifically, alterations in Akt and glycogen synthase kinase-3β protein expression in HF + SAT animals compared with HF + NC animals may be involved in mediating myocardial insulin resistance. "
|4.||Type 2 Diabetes Mellitus (MODY)
12/01/1995 - "Previous studies have established that activation of muscle glycogen synthase (GS) is abnormal in non-insulin-dependent diabetes mellitus (NIDDM). "
09/01/2002 - "To determine the relationships of Met416Val and XbaI polymorphism of muscle glycogen synthase (GYS1) gene and Trg64Arg variant of the beta(3)-adrenergic-receptor (beta(3)-AR) gene with type 2 diabetes mellitus (DM) and its intermediate phenotypes in the Chinese population. "
06/01/1999 - "Therefore, a defective skeletal muscle glycogen synthase activation may represent an early phenotypic expression of a genetic defect contributing to an increased risk of later development of NIDDM. "
11/01/1997 - "New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland."
02/01/1997 - "These results suggest that the XbaI polymorphism of the glycogen synthase gene cannot be used as a marker for NIDDM in the Russian population."
07/01/2011 - "[The role of glycogen synthase kinase-3 beta in the pathogenesis of liver ischemia reperfusion injury]."
05/01/2007 - "Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut."
01/05/2013 - "This suggests that β-catenin and glycogen synthase kinase-3β, both components of the Wnt signaling pathway, participate in cell apoptosis following cerebral ischemia/reperfusion injury. "
01/05/2013 - "Dickkopf-1 administration, after cerebral ischemia/reperfusion injury, results in decreased cell apoptosis, and β-catenin and glycogen synthase kinase-3β expression, in the CA1 region. "
01/05/2013 - "We investigated the role of the Wnt signaling pathway in cerebral ischemia/reperfusion injury by examining β-catenin and glycogen synthase kinase-3β protein expression in the rat hippocampal CA1 region following acute cerebral ischemia/reperfusion. "
|5.||glycogen synthase kinase 3 beta
|6.||Glycogen Synthase Kinase 3
|8.||Amyloid (Amyloid Fibrils)
|9.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|10.||Valproic Acid (Valproate, Semisodium)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)